CellSource Co

CellSource Co Liabilities

The The Liabilities of CellSource Co (4880.T) as of Oct 27, 2026 is 1.10 B JPY. In the previous year, The Liabilities was 1.13 B JPY — a change of -3.13% (lower).

Liabilities

1.10 BJPY

YoY

-3.13%

Last updated:

In 2025, CellSource Co's total liabilities amounted to 1.10 B JPY, a -3.13% difference from the 1.13 B JPY total liabilities in the previous year.

The CellSource Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
295.76 M JPY
Jan 1, 2019
243.77 M JPY
Jan 1, 2020
309.63 M JPY
Jan 1, 2021
645.58 M JPY
Jan 1, 2022
815.72 M JPY
Jan 1, 2023
689.49 M JPY
Jan 1, 2024
1.13 B JPY
Jan 1, 2025
1.10 B JPY
The CellSource Co Liabilities history
YEARLiabilitiesYoY
1.10 BJPY-3.13%
1.13 BJPY+64.10%
689.49 MJPY-15.47%
815.72 MJPY+26.35%
645.58 MJPY+108.50%
309.63 MJPY+27.02%
243.77 MJPY-17.58%
295.76 MJPY+147.35%
119.57 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing CellSource Co's Liabilities

CellSource Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CellSource Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing CellSource Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

CellSource Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in CellSource Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about CellSource Co stock

The Liabilities of CellSource Co is 1.10 B JPY in 2025.

The Liabilities of CellSource Co changed from 1.13 B JPY to 1.10 B JPY, representing a -3.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CellSource Co

All Key Metrics — CellSource Co